Catalent
Catalent, Inc., a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products, is headquartered in the United States. Founded in 2007, Catalent has rapidly expanded its operations across North America, Europe, and Asia, establishing a strong presence in the pharmaceutical and biotechnology industries. The company is renowned for its innovative services, including drug formulation, clinical supply, and commercial manufacturing, which are designed to enhance product performance and patient experience. Catalent's commitment to quality and efficiency has positioned it as a trusted partner for many of the world's top pharmaceutical companies. With a focus on continuous improvement and cutting-edge technology, Catalent remains at the forefront of the industry, achieving significant milestones in drug delivery and development.
DitchCarbon Score
How does Catalent's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Catalent's score of 26 is lower than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Catalent's reported carbon emissions
Catalent, headquartered in the United States, has set ambitious climate commitments aimed at significantly reducing its carbon emissions. Although specific emissions data for the most recent year is not available, the company has established clear targets for the future. Catalent commits to reducing absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 42% by FY2030, using FY2022 as the baseline year. Additionally, the company aims to cut absolute Scope 3 GHG emissions—specifically from fuel- and energy-related activities and employee commuting—by 25% within the same timeframe. Furthermore, Catalent has pledged that by FY2028, 70% of its suppliers, measured by emissions, will have science-based targets in place. These commitments align with industry standards and reflect Catalent's dedication to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector. The targets are consistent with the reductions necessary to limit global warming to 1.5°C, demonstrating the company's proactive approach to sustainability and climate responsibility.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Catalent is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
